List of Excipients in Branded Drug FLURBIPROFEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	FLURBIPROFEN SODIUM	flurbiprofen sodium	42254-023	CITRIC ACID MONOHYDRATE
Rebel Distributors Corp	FLURBIPROFEN SODIUM	flurbiprofen sodium	42254-023	EDETATE DISODIUM
Rebel Distributors Corp	FLURBIPROFEN SODIUM	flurbiprofen sodium	42254-023	HYDROCHLORIC ACID
Rebel Distributors Corp	FLURBIPROFEN SODIUM	flurbiprofen sodium	42254-023	POLYVINYL ALCOHOL
Rebel Distributors Corp	FLURBIPROFEN SODIUM	flurbiprofen sodium	42254-023	POTASSIUM CHLORIDE

Generic Drugs Containing FLURBIPROFEN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	flurbiprofen	0093-0711	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	flurbiprofen	0093-0711	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	flurbiprofen	0093-0711	FD&C BLUE NO. 1 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	flurbiprofen	0093-0711	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	flurbiprofen	0093-0711	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in FLURBIPROFEN?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
10	CELLULOSE, MICROCRYSTALLINE
10	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 1
6	FD&C BLUE NO. 1 ALUMINUM LAKE

Flurbiprofen Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Flurbiprofen is an off-patent NSAID with limited value in undifferentiated oral tablets but stronger commercial potential in localized delivery, rapid-onset products, taste-masked dosage forms, and ophthalmic formulations. The molecule is a weak acid with low aqueous solubility, high lipophilicity, and established gastrointestinal, renal, and cardiovascular safety constraints. Excipient selection should therefore focus on dissolution control, local retention, taste masking, dose uniformity, and tolerability rather than simple tablet cost reduction.

What is the formulation profile of flurbiprofen?

Flurbiprofen is a fluorinated propionic-acid NSAID used for pain and inflammation. Its established dosage forms include oral tablets and ophthalmic solutions containing flurbiprofen sodium. In some markets, flurbiprofen is also used in medicated lozenges for sore throat symptoms.

Attribute	Formulation relevance
Active ingredient	Flurbiprofen, typically racemic drug substance
Drug class	Nonsteroidal anti-inflammatory drug
Chemical class	Propionic-acid derivative
Ionization	Weak acid; pKa is approximately 4.2
Lipophilicity	High relative to many oral analgesics
Water solubility	Low and pH-dependent
BCS-related risk	Dissolution-limited oral absorption is a major development concern
Main oral risk	Gastric irritation, ulceration, bleeding, renal effects
Main ophthalmic risk	Ocular irritation, delayed healing, corneal complications in susceptible patients
Commercial status	Mature, off-patent small molecule
Primary regulatory routes	ANDA or national generic pathway for conventional products; 505(b)(2) may support differentiated delivery

The free acid is poorly soluble in water at low pH. Alkaline pH or salt formation can improve apparent solubility, but excessive alkalinity can create stability, irritation, taste, or compatibility problems. Flurbiprofen’s lipophilicity supports membrane permeation but can reduce dissolution and increase dependence on formulation conditions.

Commercially important products include oral flurbiprofen tablets and flurbiprofen sodium ophthalmic solution. U.S. labeling identifies the systemic NSAID risks associated with oral flurbiprofen and the ophthalmic risks associated with flurbiprofen sodium products.[1,2]

What excipients are most suitable for oral flurbiprofen tablets?

The strongest conventional oral strategy combines wetting, particle dispersion, rapid disintegration, and controlled microenvironmental pH. A standard immediate-release tablet does not need a novel excipient system, but it must achieve reproducible dissolution across acidic and near-neutral media.

Immediate-release tablet strategy

A practical excipient architecture may include:

• Microcrystalline cellulose or silicified microcrystalline cellulose for compactability.
• Crospovidone, croscarmellose sodium, or sodium starch glycolate for disintegration.
• Colloidal silicon dioxide to improve flow and reduce segregation.
• Sodium lauryl sulfate or another permitted wetting agent at a low level where justified by dissolution data.
• Povidone or low-viscosity hydroxypropyl cellulose as a binder.
• Magnesium stearate at controlled concentration and mixing time to avoid hydrophobic over-lubrication.
• A mild alkalizing or buffering component where necessary to improve dissolution.
• Film coating based on hypromellose, polyvinyl alcohol, or a comparable polymer.

The primary development risk is over-optimizing disintegration while leaving the drug substance agglomerated or poorly wetted. A tablet can meet disintegration specifications yet show slow or variable dissolution.

Excipient priorities by performance objective

Objective	Candidate excipient approach	Main risk
Improve wetting	Surfactant, porous carrier, hydrophilic binder	Irritation, foaming, stability
Improve dissolution	Alkaline microenvironment, micronized drug, amorphous dispersion	Chemical instability or recrystallization
Improve tablet strength	Microcrystalline cellulose, coprocessed filler	Slow disintegration at high compression
Accelerate disintegration	Crospovidone or croscarmellose sodium	Capping, friability, moisture sensitivity
Improve content uniformity	Ordered mixture, granulation, particle-size control	Scale-up segregation
Mask taste	Film coating, polymeric barrier, ion-pairing or encapsulation	Delayed release or incomplete drug release
Reduce GI exposure	Enteric or delayed-release coating	Loss of rapid analgesic onset and higher development burden

A simple direct-compression formulation is commercially attractive when the drug substance has consistent particle size and bulk density. Wet granulation may provide better content uniformity and flow but increases exposure to moisture and process heat. Dry granulation is a reasonable option where moisture sensitivity or solvent avoidance is important.

How can solubility enhancement improve flurbiprofen products?

Solubility enhancement is the main technical opportunity for oral flurbiprofen. The formulation target is rapid, reproducible dissolution without increasing systemic exposure beyond the approved therapeutic range.

Salt and pH modification

Flurbiprofen salts or alkaline microenvironments can increase dissolution by raising local pH above the drug’s pKa. This approach has several limitations:

1. Salt formation can alter hygroscopicity and solid-state behavior.
2. Strong alkalinity can impair palatability and gastric tolerability.
3. The free acid may precipitate after exposure to gastric or intestinal pH.
4. Higher dissolution does not guarantee higher or more predictable bioavailability.

A buffered tablet can be more practical than isolating a new salt form. The buffer should be selected for compatibility with the active ingredient, moisture stability, tablet hardness, and gastrointestinal tolerability.

Amorphous dispersions and lipid systems

Amorphous solid dispersions using polymers such as povidone, copovidone, or hypromellose acetate succinate can increase apparent solubility. These systems are technically more complex and require control of:

• Drug loading.
• Residual solvent.
• Moisture uptake.
• Recrystallization during storage.
• Milling and downstream compression.
• Dissolution after accelerated aging.

Lipid-based systems, self-emulsifying systems, and liquid-filled capsules may improve wetting and dissolution but are less attractive for a low-cost generic tablet. They become more relevant for rapid-onset softgel products or differentiated 505(b)(2) programs.

Particle engineering

Micronization is one of the lowest-risk approaches. It can increase surface area without introducing a new chemical form. The main controls are:

• Particle-size distribution.
• Electrostatic charging.
• Agglomeration.
• Inhalation and occupational handling exposure.
• Blend uniformity.
• Stability of the micronized material.

Nanocrystals could support rapid dissolution and lower dose loading, but the commercial case depends on measurable clinical or labeling differentiation.

What excipients are appropriate for flurbiprofen lozenges?

Flurbiprofen lozenges offer a stronger differentiation pathway than conventional tablets because they target local oropharyngeal pain and can reduce the need for swallowing a conventional tablet. The formulation must balance drug release, residence time, taste, mouthfeel, and mucosal tolerability.

Core lozenge excipient system

Typical excipient categories include:

• Isomalt, sucrose, glucose syrup, or polyols as the structural base.
• Hydroxypropyl cellulose, hypromellose, or carbomer for matrix control.
• Flavor systems such as menthol, peppermint, citrus, or berry.
• Sweeteners such as sucralose, acesulfame potassium, or steviol glycosides.
• Buffering agents to control salivary pH and drug dissolution.
• Lubricants or anti-sticking agents for compression.
• Saliva-compatible wetting agents at low levels.

A compressed lozenge should dissolve gradually, maintain acceptable mouthfeel, and avoid localized irritation. A molded lozenge can provide slower dissolution but is more sensitive to manufacturing conditions and humidity.

Taste-masking options

Flurbiprofen’s acidic and potentially bitter taste creates a material barrier to pediatric, geriatric, and over-the-counter opportunities. Suitable approaches include:

• Polymer coating of drug particles.
• Drug-resin complexes.
• Lipid or wax microencapsulation.
• Ion-pairing with a cationic counterion.
• Flavor layering with a delayed-release coating.
• Use of a low-dose local delivery format.

Taste masking must be tested after partial dissolution, not only in a short laboratory taste screen. NSAID-containing lozenges may also create a risk of accidental repeat dosing, so packaging and unit-dose presentation are part of the product strategy.

What excipients are suitable for flurbiprofen ophthalmic products?

Flurbiprofen sodium ophthalmic solution is a specialized sterile product. The principal formulation requirements are clarity, sterility, pH control, osmolality, preservative performance where applicable, and compatibility with the ocular surface.

Ophthalmic formulation priorities

A commercial ophthalmic formulation may use:

• Flurbiprofen sodium for aqueous solubility.
• A phosphate, citrate, or comparable buffer system.
• Sodium chloride, boric acid, or another tonicity adjuster.
• A preservative in multidose packaging where permitted.
• Chelating agents such as disodium edetate where justified.
• Viscosity modifiers to increase ocular residence time.
• Low-extractable, low-sorbable container-closure materials.

The pH must balance chemical stability, solubility, preservative efficacy, and ocular comfort. Increasing viscosity may extend residence time but can cause blurred vision or poor drop formation. Preservative-free unit-dose packaging is a commercial opportunity for patients with ocular-surface disease or frequent dosing, though packaging cost rises.

Ophthalmic development also requires attention to container compatibility, extractables and leachables, particulate control, and preservative sensitivity. The FDA label for flurbiprofen sodium ophthalmic solution identifies risks involving corneal healing and ocular tissue integrity, which limits aggressive excipient strategies designed only to extend residence time.[2]

What formulation patents could protect a flurbiprofen product?

A new composition-of-matter patent is not a realistic strategy for conventional flurbiprofen. Commercial protection would more likely arise from formulation, delivery, manufacturing, or method-of-use claims.

Potential claim categories include:

Patent category	Potential subject matter	Commercial strength
Salt or polymorph	Defined flurbiprofen salt, crystal form, or hydrate	Moderate if difficult to design around
Amorphous dispersion	Drug-polymer ratio and solid-state profile	Moderate, with stability dependence
Nanocrystal formulation	Particle size, stabilizer system, dissolution profile	Moderate
Mucoadhesive lozenge	Polymer matrix, residence time, release profile	Moderate
Ophthalmic composition	pH, viscosity, preservative-free packaging, stability	Moderate
Transdermal system	Adhesive, permeation enhancer, flux, patch architecture	Potentially strong if clinically differentiated
Manufacturing process	Milling, granulation, coating, or sterilization process	Narrow but useful as a manufacturing barrier
Method of use	Local pain, post-operative ocular inflammation, or selected populations	Usually vulnerable to design-around or obviousness challenges

Patent value depends on whether the formulation produces an identifiable clinical or regulatory benefit. A narrow excipient list without a meaningful performance limitation is more exposed to invalidity and design-around arguments.

Because flurbiprofen is an old small molecule, any U.S. Orange Book value is more likely to come from currently listed product-specific patents, if any, than from original drug exclusivity. Conventional flurbiprofen tablet products do not retain meaningful new chemical entity exclusivity. Generic applicants can use ANDA pathways when the reference product and regulatory conditions are available; differentiated dosage forms may require a 505(b)(2) strategy.

When did flurbiprofen lose exclusivity?

Flurbiprofen lost the commercial protection associated with its original small-molecule approval years ago. It is now an established generic active ingredient, and the principal competitive barriers are formulation execution, regulatory requirements, manufacturing reliability, and channel access.

Exclusivity category	Current strategic relevance
New chemical entity exclusivity	Expired
Original composition patent	Expired or commercially irrelevant
Conventional oral tablet protection	Generic competition
Ophthalmic product protection	Product-specific regulatory and formulation barriers may remain, but not NCE exclusivity
New formulation patents	Available only for newly developed technology
Method-of-use patents	Potentially available for differentiated indications, subject to validity and enforceability
Orphan exclusivity	Not central to standard flurbiprofen products

A Paragraph IV opportunity would require an active, listed patent covering the targeted reference product. For an ordinary flurbiprofen tablet, the opportunity is generally an abbreviated generic filing rather than a high-value patent challenge. For an innovative ophthalmic, transdermal, or modified-release product, patent disputes would center on formulation and use claims.

What is the FDA regulatory status and Orange Book position?

Flurbiprofen has established FDA regulatory precedent in oral and ophthalmic dosage forms. The regulatory pathway depends on the product being copied or developed.

Conventional oral product

An oral tablet that matches an approved reference product can generally pursue an ANDA, subject to pharmaceutical equivalence, bioequivalence, manufacturing controls, labeling, and product-specific FDA requirements.

Ophthalmic product

A sterile ophthalmic solution requires tighter controls over:

• Sterility assurance.
• Visible and subvisible particles.
• pH and osmolality.
• Preservative efficacy.
• Container closure.
• Drop size and delivered volume.
• Stability after opening.

Differentiated product

A modified-release, transdermal, buccal, or locally retained product may need a 505(b)(2) application if it relies on prior findings for flurbiprofen while introducing a new dosage form, route, formulation, or clinical use. The commercial benefit must justify the higher clinical and regulatory burden.

The FDA’s Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. For an off-patent active ingredient such as flurbiprofen, Orange Book analysis is product-specific rather than molecule-wide.[3]

What commercial opportunities exist for flurbiprofen?

The highest-value opportunities are differentiated products that solve a known limitation of NSAID therapy.

1. Rapid-onset oral formulation

A micronized, wetting-enhanced, or pH-modified tablet could compete on onset and dissolution. The product would need a clinically credible benefit rather than only an in vitro dissolution improvement.

2. Low-dose oropharyngeal lozenge

A lozenge can target sore throat pain through local delivery and consumer convenience. Commercial success depends on taste, duration of relief, dosing frequency, and regulatory classification.

3. Preservative-free ophthalmic product

A unit-dose or multidose preservative-free product could target patients who need repeated ocular treatment or have preservative sensitivity. The main barriers are packaging cost, sterility, stability, and manufacturing scale.

4. Transdermal or topical delivery

Flurbiprofen’s lipophilicity supports investigation of topical delivery. Commercially relevant formats include gels, patches, sprays, and localized films. The key challenge is achieving useful tissue exposure without excessive skin irritation or inconsistent flux.

5. Fixed-dose combinations

Combination products could pair flurbiprofen with a local anesthetic, antiseptic, counterirritant, or another analgesic. Combination development faces clinical justification, interaction, labeling, and dosing-complexity requirements.

6. Veterinary products

Veterinary topical or oral products may offer niche opportunities, but species-specific pharmacokinetics, residue controls, palatability, and veterinary regulatory requirements create separate development programs.

How strong is the flurbiprofen patent estate?

The core flurbiprofen patent estate is weak because the active ingredient is old and widely genericized. A new product can still create a defensible position through formulation and manufacturing claims.

Relative strength by product type

Product	Patent strength	Generic substitution risk	Main barrier
Standard oral tablet	Low	High	Price and supply reliability
Rapid-dissolution tablet	Low to moderate	Moderate to high	Demonstrating clinical relevance
Lozenge	Moderate	Moderate	Taste, release, and trade-channel access
Ophthalmic solution	Moderate	Moderate	Sterility, packaging, and preservative system
Preservative-free ophthalmic product	Moderate	Moderate	Container and manufacturing cost
Transdermal patch	Moderate to high	Moderate	Flux, adhesion, skin tolerability, clinical proof
Amorphous dispersion	Moderate	Moderate	Solid-state stability and process reproducibility
Nanocrystal product	Moderate	Moderate	Scale-up and regulatory justification

The most defensible programs combine a patentable formulation with a measurable product attribute, such as extended local residence, defined release kinetics, reduced dosing frequency, or preservative-free administration.

Which companies are challenging flurbiprofen products?

Competition is fragmented across generic manufacturers, contract manufacturers, ophthalmic specialists, and consumer-health companies. The market does not depend on a single originator defending a large branded franchise.

For conventional tablets, competitive pressure comes from low-cost generic suppliers. For ophthalmic products, sterile manufacturing capacity and regulatory execution matter more than raw ingredient access. For lozenges and consumer products, flavor development, packaging, retail distribution, and local regulatory classification can determine market access.

No material current Paragraph IV campaign or settlement structure is central to the ordinary flurbiprofen market. The more relevant commercial question is whether a developer can create a product that is difficult to substitute therapeutically, not whether it can preserve exclusivity on the molecule.

What generic launch risks exist for flurbiprofen?

Generic entry risk is high for standard oral tablets and lower for complex dosage forms.

Key launch risks include:

• Bioequivalence failure caused by dissolution variability.
• Drug-substance particle-size shifts between suppliers.
• Content-uniformity problems at low dose.
• Tablet sticking or capping during compression.
• Taste-mask failure in lozenges.
• Preservative instability in ophthalmic products.
• Container-closure adsorption or extractables.
• Post-approval changes affecting dissolution.
• Competitive price erosion.
• Limited reimbursement for a reformulated product without clinical differentiation.

A formulation developer should prioritize excipient robustness across suppliers. Reliance on a single proprietary grade can create supply and change-control exposure unless the excipient is essential to product performance.

How should a commercial excipient strategy be structured?

A practical strategy has three tiers.

Tier 1: Low-cost generic tablet

Use conventional, widely available excipients. Focus on dissolution, blend uniformity, compression, and supply continuity. This is the lowest-risk but least differentiated opportunity.

Tier 2: Differentiated local-delivery product

Use mucoadhesive, taste-masking, viscosity-building, or preservative-free technologies. Protect the formulation with performance-based patents and seek a regulatory pathway that recognizes the new dosage form.

Tier 3: Advanced delivery platform

Use nanocrystals, amorphous dispersion, transdermal systems, or long-residence ophthalmic technology. This tier requires stronger clinical justification, more complex manufacturing, and a higher price proposition.

Excipient selection should be linked to a commercial claim. "Fast dissolving," "longer local residence," "preservative-free," and "better taste" are development objectives only when supported by validated performance and, where necessary, clinical evidence.

Key Takeaways

• Flurbiprofen is an off-patent NSAID with high generic pressure in conventional oral tablets.
• The principal technical challenge is low, pH-dependent aqueous solubility.
• Immediate-release tablets should prioritize wetting, particle dispersion, disintegration, and dissolution robustness.
• Lozenges offer a stronger consumer and local-delivery opportunity, but taste masking and dose control are critical.
• Ophthalmic products require sterile processing, pH and osmolality control, preservative management, and container-closure compatibility.
• The most defensible patents will cover formulation performance, local retention, release behavior, or manufacturing process controls.
• Transdermal, preservative-free ophthalmic, rapid-onset, and taste-masked products have greater commercial potential than another conventional tablet.
• Paragraph IV value is limited for ordinary flurbiprofen products because core exclusivity has expired and competition is primarily generic.
• Revenue upside depends on dosage-form differentiation, regulatory positioning, and channel access rather than molecule ownership.

FAQs

Is flurbiprofen suitable for an orally disintegrating tablet?

Yes, but taste masking and dissolution control are essential. An orally disintegrating tablet may improve convenience, but it does not automatically reduce gastrointestinal or systemic NSAID risks.

Can flurbiprofen be formulated as a sustained-release product?

Yes. Sustained release can use hydrophilic matrix polymers, multiparticulates, or coated pellets. The commercial case is limited unless reduced dosing frequency or improved tolerability is demonstrated.

Does flurbiprofen require a solubilizer?

Not always. Conventional tablets can use micronization and wetting agents. A solubilizer or pH modifier becomes more relevant when the target is rapid dissolution, low-dose content uniformity, or a liquid dosage form.

Is flurbiprofen a good candidate for pediatric medicines?

It may be suitable for selected local-delivery products, but pediatric development requires careful dose flexibility, taste masking, excipient acceptability, and age-specific safety assessment. A liquid formulation can create solubility and preservative challenges.

What is the most attractive flurbiprofen product concept?

A taste-masked local lozenge or a preservative-free ophthalmic product has a stronger differentiation profile than a standard tablet. A transdermal system may offer the largest patent opportunity but also carries the highest clinical and manufacturing risk.

References

1. U.S. Food and Drug Administration. (n.d.). Flurbiprofen tablets prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.). Flurbiprofen sodium ophthalmic solution prescribing information. FDA labeling database.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. National Center for Biotechnology Information. (n.d.). PubChem compound summary for flurbiprofen. PubChem.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.

6. International Council for Harmonisation. (2005). ICH Q9: Quality risk management.

7. International Council for Harmonisation. (2008). ICH Q10: Pharmaceutical quality system.